We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
An image displaying a Newsletter on tablet, laptop & mobile

To continue reading this article, sign up for FREE to

Technology Networks logo


Membership is FREE and provides you with instant access to email newsletters, digital publications, our full content catalogue & more...

CMD Bioscience and Research Foundation of SUNY on Behalf of Stony Brook University Sign Exclusive Licensing Agreement

Read time: Less than a minute

CMD Bioscience LLC has signed an exclusive licensing agreement with the Research Foundation of SUNY on behalf of Stony Brook University.

The deal gives CMD Bioscience exclusive control of a computational method for predicting protein-protein and protein-peptide binding affinities. The algorithm has enormous implications for computer-aided drug design.

“We are very excited about obtaining an exclusive license for this software from the Research Foundation of SUNY on behalf of Stony Brook University,” said Dr. Joseph Audie, the CEO and founder of CMD Bioscience. “This program gives us a competitive advantage and enhances our ability to rationally design proteins and peptides for our biotech and pharmaceutical partners.”

CMD Bioscience is a Connecticut-based company that uses proprietary computational methods to solve problems of biological and therapeutic interests. Formed in 2006, the company was founded by Dr. Joseph Audie of Meriden, CT., Ph.D.

Google News Preferred Source Add Technology Networks as a preferred Google source to see more of our trusted coverage.